Mercury Systems (NASDAQ:MRCY) vs. Mainz Biomed (NASDAQ:MYNZ) Head-To-Head Contrast

Mercury Systems (NASDAQ:MRCY) and Mainz Biomed (NASDAQ:MYNZ) are both industrials companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings for Mercury Systems and Mainz Biomed, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mercury Systems	2	3	7	1	2.54
Mainz Biomed	1	1	0	0	1.50

Mercury Systems presently has a consensus target price of $108.00, suggesting a potential upside of 22.27%. Given Mercury Systems’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Mercury Systems is more favorable than Mainz Biomed.

Profitability

This table compares Mercury Systems and Mainz Biomed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mercury Systems	-0.40%	2.55%	1.55%
Mainz Biomed	N/A	N/A	N/A

Insider and Institutional Ownership

96.0% of Mercury Systems shares are held by institutional investors. 1.0% of Mercury Systems shares are held by insiders. Comparatively, 18.2% of Mainz Biomed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Mercury Systems and Mainz Biomed”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mercury Systems	$983.62 million	5.47	-$29.67 million	($0.50)	-176.66
Mainz Biomed	$659,935.00	9.48	-$21.65 million	($65.60)	-0.01

Mainz Biomed has lower revenue, but higher earnings than Mercury Systems. Mercury Systems is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Mercury Systems has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500.

Summary

Mercury Systems beats Mainz Biomed on 10 of the 15 factors compared between the two stocks.

About Mercury Systems

Mercury Systems, Inc. develops and supplies secure processing systems and subsystems for the aerospace and defense industries. Its products include embedded computing, signal processing, radio-frequency and microwave components, and other technologies used to process and manage critical data. The company’s technologies support applications such as radar, electronic warfare, communications, avionics, and command-and-control systems. Mercury works with defense contractors and government customers, providing components and systems designed for use in demanding environments.

About Mainz Biomed

Mainz Biomed N.V. is a molecular genetics diagnostic company focused on developing noninvasive tests for the early detection of cancer. The company was founded in 2016 and is headquartered in Mainz, Germany, with operations and commercial activities serving markets in Europe and the United States. Mainz Biomed’s principal product is ColoAlert, an at-home, stool-based colorectal cancer screening test. The test analyzes molecular biomarkers, including genetic and epigenetic changes associated with colorectal cancer, and is designed to provide a convenient alternative to certain conventional screening methods.